Silencing FASN in prostate cancer leads to a reduction of RhoU palmitoylation and decreases the protein stability of Cdc42, which is connected to the suppression of migration and invasion (De Piano et al. 2020, 2021). This evidence concerns the gene FASN and Familial prostate cancer.